Neuronascent, Inc.
Neuronascent is a biotechnology company focused on generating new neurons and reversing neurological disorders. It develops small-molecule therapeutics aimed at neurogenesis and neuron regeneration, with ongoing R&D programs targeting diseases such as Alzheimer’s and Parkinson’s. The company is led by a team of experienced scientists and industry professionals dedicated to advancing neuroregenerative therapies.
Industries
Nr. of Employees
small (1-50)
Neuronascent, Inc.
6030 Day Break Circle, A150 – PMB244, Clarksville, MD 21029
Patents
Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones
US-9592234-B2
View DetailsMethods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration
US-9539261-B2
View DetailsMethods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones
US-9096613-B2
View DetailsMethods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration
US-8999972-B2
View DetailsMethods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones
US-8609840-B2
View DetailsMethods and compositons for stimulating neurogenesis and inhibiting neuronal degeneration
US-8039462-B2
View Details
Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones
US-9592234-B2
View DetailsMethods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration
US-9539261-B2
View DetailsMethods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones
US-9096613-B2
View DetailsMethods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration
US-8999972-B2
View DetailsMethods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones
US-8609840-B2
View DetailsMethods and compositons for stimulating neurogenesis and inhibiting neuronal degeneration
US-8039462-B2
View DetailsProducts
Small-molecule neuroregenerative clinical candidate (early-phase)
Orally administered small-molecule therapeutic candidate developed to stimulate neurogenesis and reverse cognitive deficits; progressed to Phase 1a safety testing in older adults.
Small-molecule neuroregenerative preclinical candidate with orphan/rare pediatric designations
Preclinical-stage therapeutic candidate targeting developmental and pediatric neurodevelopmental disorders, with regulatory orphan and rare pediatric drug designations.
Small-molecule neuroregenerative clinical candidate (early-phase)
Orally administered small-molecule therapeutic candidate developed to stimulate neurogenesis and reverse cognitive deficits; progressed to Phase 1a safety testing in older adults.
Small-molecule neuroregenerative preclinical candidate with orphan/rare pediatric designations
Preclinical-stage therapeutic candidate targeting developmental and pediatric neurodevelopmental disorders, with regulatory orphan and rare pediatric drug designations.
Services
Partnerships with academic and research institutions for translational studies, including studies in companion animals to model age-related cognitive decline.
Partnerships with academic and research institutions for translational studies, including studies in companion animals to model age-related cognitive decline.
Expertise Areas
- Neuroregenerative therapeutics
- Small-molecule CNS drug discovery
- Preclinical model development
- Clinical trial management (early-phase)
Key Technologies
- Small-molecule therapeutics
- Allosteric kinase modulation
- Neurogenesis-stimulating pharmacology
- Progressive MPTP Parkinson's disease model
News & Updates
Collaboration with University of Alaska Fairbanks to study Canine Cognitive Disorder (CCD) in older dogs.
Neuronascent announces NIA grant award for NNI-362 to reach Phase 2 clinical trials for Alzheimer’s disease.
Longevity Technology News recognizes significant advancement of NNI-362 for Alzheimer’s treatment.
Neuronascent to present new Parkinson’s model data at AAIC 2023 for NNI-362.
CEO to present on therapy-induced neuron genesis at the World Orphan Drug Congress 2023.
Neuronascent to present further NNI-362 Phase 1a data at CTAD 2022.
Collaboration with University of Alaska Fairbanks to study Canine Cognitive Disorder (CCD) in older dogs.
Neuronascent announces NIA grant award for NNI-362 to reach Phase 2 clinical trials for Alzheimer’s disease.
Longevity Technology News recognizes significant advancement of NNI-362 for Alzheimer’s treatment.
Neuronascent to present new Parkinson’s model data at AAIC 2023 for NNI-362.
CEO to present on therapy-induced neuron genesis at the World Orphan Drug Congress 2023.
Neuronascent to present further NNI-362 Phase 1a data at CTAD 2022.